HGF and neoplasm: For the patients with KRAS mutation, Cuneo et al. conducted a cell experiment and found that the application of crizotinib, a tyrosine kinase inhibitor (TKI), targeting c-Met gene expression could shorten the stagnation of tumor cells in G1 phase, and block hepatocyte growth factor (HGF).